U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C65H87N14O19S2.Lu
Molecular Weight 1609.5471
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LUTETIUM OXODOTREOTIDE LU-177

SMILES

C[C@]([H])([C@@]1([H])C(=N[C@@]([H])(CSSC[C@@]([H])(C(=N[C@@]([H])(Cc2ccc(cc2)[O-])C(=N[C@]([H])(Cc3c[nH]c4ccccc34)C(=N[C@@]([H])(CCCCN)C(=N1)O)O)O)O)N=C([C@@]([H])(Cc5ccccc5)N=C(CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)O)CC(=O)O)[O-])O)C(=N[C@@]([H])([C@@]([H])(C)O)C(=O)O)O)O)O.[Lu+3]

InChI

InChIKey=MXDPZUIOZWKRAA-PRDSJKGBSA-K
InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2

HIDE SMILES / InChI

Molecular Formula C65H87N14O19S2
Molecular Weight 1432.6034
Charge -3
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Lu
Molecular Weight 176.9438
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LUTATHERA

Approved Use

LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Launch Date

1.51683845E12
PubMed

PubMed

TitleDatePubMed
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
2018 Sep 10
Patents

Patents

Sample Use Guides

The recommended LUTATHERA® (lutetium Lu 177 dotatate) dose is 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.
Route of Administration: Intravenous
SSTR-mediated uptake of 177Lu-DOTATATE by various cell lines was measured after 4 h incubation with 100 KBq/ml 177Lu-DOTATATE in the presence or in the absence of 1 μM octreotide
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:39:43 UTC 2021
Edited
by admin
on Fri Jun 25 20:39:43 UTC 2021
Record UNII
AE221IM3BB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LUTETIUM OXODOTREOTIDE LU-177
Common Name English
LUTETATE(1-)-177LU, (N-((4,7,10-TRIS((CARBOXY-.KAPPA.O)METHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL-.KAPPA.N1,.KAPPA.N4,.KAPPA.N7,.KAPPA.N10)ACETYL)-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-CYSTEINYL-L-THREONINE CYCLIC (2-7)-DIS
Systematic Name English
LUTETIUM LU 177 DOTATATE
Common Name English
177LU-DOTATATE
Common Name English
LUTETIUM DOTATATE LU-177 [ORANGE BOOK]
Common Name English
(177)LU-DOTATATE
Common Name English
LUTETIUM (177LU) OXODOTREOTIDE
INN  
INN  
Official Name English
LUTETIUM (177LU) OXODOTREOTIDE [MI]
Common Name English
LUTETIUM-177(3+), S2,S7-CYCLO(N-(4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL)-4-CHLORO-L-PHENYLALANYL-D-CYSTEINYL-4-((4S)-2,6-DIOXO-1,3-DIAZINANE-4-CARBOXAMIDO)-L-PHENYLALANYL-4-(CARBAMOYLAMINO)-D-PHENYLALANYL-L-LYSYL-L-THREONYL-L-
Systematic Name English
((177)LU-DOTA(0)-TYR(3))-OCTREOTATE
Common Name English
LUTETIUM (177LU) OXODOTREOTIDE [INN]
Common Name English
LUTETIUM DOTATATE LU-177
Common Name English
LUTATHERA
Brand Name English
OXODOTREOTIDE LUTETIUM, LU-177
Common Name English
DOTATATE LUTETIUM LU-177
Common Name English
177LU-DOTA-TYR3-OCTREOTATE
Common Name English
LUTETIUM LU-177 DOTATATE
Common Name English
DOTA-OCTREOTATE LUTETIUM LU-177
Common Name English
OXODOTREOTIDE LUTETIUM LU-177
Common Name English
LUTETIUM DOTATATE, LU-177
Common Name English
DOTATATE LUTENIUM LU-177
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 271008
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
NCI_THESAURUS C129819
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
EU-Orphan Drug EU/3/07/523
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
NCI_THESAURUS C2124
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
WHO-ATC V10XX04
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
Code System Code Type Description
INN
10470
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
EVMPD
SUB180110
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
LACTMED
Lutetium Lu 177 Dotatate
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
MERCK INDEX
M12054
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
CAS
437608-50-9
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
PUBCHEM
76966897
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
RXCUI
1999335
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
DRUG CENTRAL
5275
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
NCI_THESAURUS
C95020
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
EPA CompTox
437608-50-9
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
DRUG BANK
DB13985
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
FDA UNII
AE221IM3BB
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
PRIMARY
CAS
753443-19-5
Created by admin on Fri Jun 25 20:39:43 UTC 2021 , Edited by admin on Fri Jun 25 20:39:43 UTC 2021
ALTERNATIVE
Related Record Type Details
TARGET->RADIOLIGAND
Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.
BINDER->LIGAND
BINDING
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC COMMENTS
PHARMACOKINETIC